Background {#Sec1}
==========

In the Netherlands, over 6200 patients with End Stage Renal Disease (ESRD) are dependent on dialysis, and over the past 15 years, the number of dialysis patients has increased by more than 20% \[[@CR1]--[@CR3]\]. The burden of dialysis is high and the health-related quality of life (HRQoL), which is presently considered to be the most important outcome parameter in dialysis patients, is much worse than that of healthy people \[[@CR4]\]. As patient survival is poor, with a median five-year survival rate of only 45%, optimising HRQoL is of great importance for this growing group of patients \[[@CR5], [@CR6]\].

Besides its impact on HRQoL, dialysis is also an expensive treatment. In the Netherlands, the estimated costs are approximately 570 million euro per year (639 million US dollars) and are still increasing. \[Personal communications, G.A. De Wit, National Institute for Public Health and the Environment, 2019\] This makes dialysis by far the highest cost-consuming treatment in internal medicine, not only calculated per individual patient, but also if total treatment costs are taken into account \[[@CR7]\].

Home dialysis has a potential positive effect on HRQoL because it offers flexibility to patients and greater freedom \[[@CR8]\]. Moreover, home dialysis is possibly a more cost-effective therapy if less nursing staff is needed, when patients perform their treatment autonomously or with help of an informal caregiver. Despite these potential advantages, currently more than 80% of dialysis patients are treated with in-centre haemodialysis (ICHD). Furthermore, the percentage of patients treated with home dialysis is steadily decreasing in the Netherlands, from 32% in 2002 to 18% in 2018. This decline is mainly attributable to a reduction in the number of patients performing peritoneal dialysis (PD), the main home based therapy, with 1519 PD patients (30% of total dialysis patients) in 2002 versus 894 PD patients (14% of total dialysis patients) in 2018 \[[@CR1]\].

Available evidence regarding the effects of home dialysis compared with ICHD on HRQoL, a Patient Reported Outcome (PRO), is limited. Most studies have a cross-sectional design and lack adequate correction for confounding among dialysis groups \[[@CR9]--[@CR38]\]. Also, the characteristics of patients starting with some kind of home dialysis treatment have changed remarkably over the past years. Previously, those patients were typically young, working people with little comorbidities, whereas during the last years the general home dialysis population is older and often suffers from multiple comorbidities \[[@CR2]\]. This could influence clinical outcomes such as mortality and hospitalisation rate. Finally, there are limited data available regarding the cost-effectiveness of home dialysis.

To investigate the effect of home dialysis on HRQoL, clinical outcomes, and costs, the Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes (DOMESTICO) has been initiated. The aim of this study is to compare HRQoL, clinical outcomes, and cost-effectiveness of home dialysis with ICHD. The hypothesis is that home dialysis is associated with better HRQoL, at least comparable clinical outcomes and lower costs, compared to ICHD.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

DOMESTICO is a nationwide, prospective, observational cohort study comparing home dialysis with ICHD. The maximum follow-up period of the study is 48 months. At present, 53 Dutch dialysis centres (covering 96% of Dutch centres) and 1 Belgian dialysis centre have agreed to recruit patients (Fig. [1](#Fig1){ref-type="fig"}). The study is conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO). Fig. 1Participating centres. The red dots indicate the participating centres: 53 Dutch dialysis centres (covering 96% of Dutch centres) and 1 Belgian dialysis centre

Study population {#Sec4}
----------------

All patients, aged 18 years and older, with ESRD that start with a form of dialysis in the participating centres, between December 2017 and December 2020, are eligible for this study. These patients are allowed to have a history of renal replacement therapy (RRT), however they have to (re) start dialysis during the study period for example due to kidney transplant failure (with or without previous dialysis). All these patients are defined as 'incident patients'. Prevalent dialysis patients, and patients with a life expectancy shorter than 3 months or an expected kidney transplantation within 3 months, are excluded. Patients have to provide written informed consent before participating in the study.

Inclusion {#Sec5}
---------

Patients are included in the period within four weeks before to four weeks after start of dialysis. If patients are missed for inclusion within this timeframe (for example, due to acute start of dialysis), they can be included at 3 months (± 2 weeks) after start of dialysis. Start of dialysis is defined as the first PD session performed at (a nursing) home (excluding PD-training) or, in case of ICHD, the first haemodialysis session performed in a centre (excluding continuous RRT).

The first patient was included in December 2017 and the study has currently started in 45 centres with 338 participating patients (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Participating patients

(Early) termination {#Sec6}
-------------------

For each participating patient, the study ends on 20 December 2021. Early study termination occurs if the patient withdraws from the study or stops dialysis treatment. Reasons to stop dialysis include kidney transplantation, recovery of kidney function, the wish to stop dialysis, or death.

Outcomes {#Sec7}
--------

### Primary outcome parameter {#Sec8}

The primary outcome parameter is the patient's HRQoL, a PRO, determined with the 12-item Short Form (SF-12) health survey and the Dialysis Symptom Index (DSI) \[[@CR39], [@CR40]\]. These questionnaires were carefully selected as Patient Reported Outcome Measures (PROMs) in nephrological care by the Dutch Kidney Patients Association, the Dutch Federation for Nephrology, Nefrovisie (the Dutch Quality Institute for Nephrology), and Leiden University Medical Center \[[@CR41], [@CR42]\].

The SF-12 is the shorter version of the Short Form-36 (SF-36), one of the most widely used surveys to assess HRQoL \[[@CR43], [@CR44]\]. The SF-36 consists of eight domains: Physical functioning, Role-physical, Bodily pain, General health, Vitality, Social function, Role-emotional and Mental health. These domains are summarised in the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. In the SF-12 these summary scores are calculated from the 12 most important questions (explaining \~ 90% variance) of the SF-36 questionnaire \[[@CR39], [@CR45]\]. As the average difference in summary scores between SF-36 and SF-12 is quite small, for time-efficiency reasons, the SF-12 can be used reliably in cohort studies \[[@CR46]\].

The DSI consists of 30 questions evaluating the severity of symptoms relevant to dialysis and ESRD patients (Table [1](#Tab1){ref-type="table"}). Patients report the level of burden of specific symptoms on a 5-point Likert scale, options range from 'not at all bothersome' to 'very bothersome' \[[@CR40]\]. Table 1Items Dialysis Symptom Index1. Constipation16. Chest pain2. Nausea17. Headache3. Vomiting18. Muscle soreness4. Diarrhoea19. Difficulty concentrating5. Decreased appetite20. Dry skin6. Muscle cramps21. Itching7. Swelling in legs22. Worrying8. Shortness of breath23. Feeling nervous9. Lightheadedness or dizziness24. Trouble falling asleep10. Restless legs or difficulty keeping legs still25. Trouble staying asleep11. Numbness or tingling in feet26. Feeling irritable12. Feeling tired or lack of energy27. Feeling sad13. Cough28. Feeling anxious14. Dry mouth29. Decreased interest in sex15. Bone or joint pain30. Difficulty becoming sexually aroused

### Secondary outcome parameters {#Sec9}

Secondary outcome parameters are hospitalisation, mortality, other clinical parameters, costs, and technique failure.

The cause of each hospitalisation episode will be categorised into the following categories (using ICD-10 codes) \[[@CR47]\]: Cardiac (including myocardial ischaemia/infarction, cardiac arrest/arrhythmia, cardiac failure, fluid overload/pulmonary edema, haemorrhagic pericarditis);Vascular disease (including pulmonary embolus, stroke, cerebrovascular haemorrhage, ruptured vascular aneurysm, mesenteric infarction, peripheral arterial disease);Infection, non-dialysis related (including bacteraemia/sepsis, cardiac infection, HIV, osteomyelitis, respiratory infection, urinary tract infection);Dialysis related (including dialysis access infection, peritonitis, PD catheter leakage/exchange/removal, fistula operation, renal fluid overload, bleeding);Malignancy;Bleeding, non-dialysis related (including intracranial bleeding, gastro-intestinal bleeding, other causes of bleeding);Other causes.

Mortality will be categorised into the following categories (using ERA-EDTA codes) \[[@CR48]\]: Sudden death 'with unknown cause';Cardiac (including myocardial ischaemia/infarction, cardiac arrest/arrhythmia, cardiac failure, fluid overload/pulmonary edema, haemorrhagic pericarditis);Vascular (including pulmonary embolus, stroke, cerebrovascular haemorrhage, ruptured vascular aneurysm, mesenteric infarction, peripheral arterial disease);Infectious, dialysis related (including dialysis access infection, peritonitis);Infectious, non-dialysis related (including bacteraemia/sepsis, cardiac infection, HIV, osteomyelitis, respiratory infection, urinary tract infection);Malignancy;Bleeding (including dialysis related bleeding, intracranial bleeding, gastro-intestinal bleeding, other causes of bleeding);Overall deterioration in clinical condition/stopping dialysis;Other causes.

Besides hospitalisation and mortality, several clinical parameters will be recorded including blood pressure and use of antihypertensive drugs, haemoglobin and use of erythropoiesis-stimulating agents, phosphate levels and use of phosphate binders, vascular access parameters, and nutritional status.

Direct healthcare costs, patient costs, and costs with regard to productivity losses will be assessed with a subset of questions from the Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) and the iMTA Medical Cost Questionnaire (iMCQ) \[[@CR49], [@CR50]\]. To capture all health care costs for the population under research a small number of disease specific services are added to the standard iMCQ, e.g. home dialysis. Given the fact that many patients need substantial help from close relatives, also use of informal care by patients will be assessed. The costs related to the healthcare consumption, the dialysis procedures, the diagnostic tests and (over-the-counter) medication will be derived from the patient's medical chart during the study. Unit costs will be derived from the Dutch manual for costing studies \[[@CR51]\].

To further examine cost-effectiveness, the EuroQol-5D-5L (EQ5D-5L) questionnaire will be used. The EQ-5D-5L measures HRQoL on the following 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has 5 levels of functioning, ranging from 'no problems' to 'extreme problems'. The EQ-5D-5L also contains a visual analogue scale on which the current health state can be indicated. The EQ-5D scores can be used to calculate utilities, which describe HRQoL on a scale from 0 (dead) to 1 (perfect health). Utilities can be combined with survival to calculate quality adjusted life years (QALYs). As outcome measure for cost-effectiveness, the costs per additional QALY will be analysed \[[@CR52], [@CR53]\].

All participating patients will also receive a self-management screening questionnaire (SeMaS) at baseline, in order to investigate whether self-management can predict a successful home dialysis treatment. This questionnaire shows the abilities and possible barriers for self-management by asking questions about the burden of disease, locus of control, self-efficacy, social support, coping style, anxiety, depression, and skills \[[@CR54], [@CR55]\].

Table [2](#Tab2){ref-type="table"} provides an overview of the moments when participating patients will fill in the aforementioned questionnaires. Table 2Overview questionnairesVisitSF-12\
and DSIiPCQ\
and iMCQEQ-5D-5LSeMaSBaselineXXXXAt 3 and 6 monthsXXXAt 9 months and every 6 months thereafterXAt 12 months and every 6 months thereafterXXX*SF-12* Short Form-12, *DSI* Dialysis Symptom Index, *iPCQ* Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire, *iMCQ* iMTA Medical Cost Questionnaire, *SeMaS* self-management screening questionnaire

Finally, technique failure rate of home dialysis, defined by a composite outcome of death or transfer to ICHD, will be assessed. Both a 30-days and a 180-days definition of technique failure will be used according to the minimum number of days the patient received ICHD after cessation of home dialysis \[[@CR56]\]. Permanent technique failure is defined by death or transfer to ICHD (using the 180-days definition), or cessation of dialysis. Death-censored technique failure will be reported separately. Transfer to kidney transplantation is not considered to be technique failure and will also be reported separately \[[@CR56]\].

Data collection {#Sec12}
---------------

All study outcomes, except the SeMaS, will be assessed at baseline, after 3 months, 6 months, and thereafter every 6 months until end of follow-up or end of the study (Table [2](#Tab2){ref-type="table"}).

Data will be registered in case report forms (CRF). IBM Data Collection will be used as CRF. The database is developed by Nefrovisie and follows the principles of Good Clinical Practice (i.e. it has an audit trail, possibility for electronic signing, direct validation of inserted data, authorisation per form and user). Nefrovisie will also host the database for the duration of the study. The database will be archived for future research during 15 years after termination of the study.

Statistical analysis {#Sec13}
--------------------

All statistical analyses will be performed using statistical software such as SPSS and Stata. Univariable and multivariable regression analysis will be conducted. In case of repeated measures, multilevel analysis or generalised estimating equations will be applied. Possible confounders determined a priori are age, gender, marital status, level of education, work status, cause of renal failure, prior RRT with dialysis vintage, comorbidities, albumin, body mass index, and protein energy wasting. Cumulative incidence of hospitalisation, mortality, and technique failure will be reported in Kaplan Meier curves. In case of missing data, multiple imputation techniques will be used to impute the missing values where appropriate.

Overall costs will be compared across the treatment groups and 95% confidence intervals will be estimated using bootstrapping techniques. The cost-effectiveness of different dialysis modalities will be determined using a state transition model. This model captures the changes in treatment modality, including transplantation, over time. The results of the DOMESTICO study will be used as input parameters for this model.

Sample size calculation {#Sec14}
-----------------------

For the primary outcome HRQoL, obtained with the SF-12, a sample size of 350 patients is required. To obtain a clinically relevant difference between groups of 3 points in the SF-12 summary scores, after a median of 12 months follow-up, 175 patients per group are needed (assumed standard deviation = 10 points, α = 0.05, β = 0.20) \[[@CR46], [@CR57]--[@CR59]\].

However, for the EQ5D-5L, an important component for the secondary outcome cost-effectiveness, a sample size of 1400 patients (700 patients per group) is needed. A difference of 0.03--0.07 points between groups after a mean follow-up of 12 months is considered clinically relevant \[[@CR44], [@CR60], [@CR61]\]. The standard deviation in dialysis groups ranges from 0.1 to 0.22 \[[@CR62], [@CR63]\]. Assuming a common standard deviation of 0.20 and the lowest, still clinically relevant score, a total of 1400 patients (700 patients per group) will be sufficient to detect a difference of 0.03 points in the EQ5D-5L score between groups (α = 0.05, β = 0.20).

When approximately 10% loss to follow up is taken into account, a group of 800 home dialysis patients and a comparison group of 800 ICHD patients has to be included in order to have sufficient power to analyse both outcomes. Since the ratio between PD patients and home haemodialysis (HHD) patients in the Netherlands is expected to be 3:1 in future years, the home dialysis group will consist of 600 PD and 200 HHD patients.

Discussion {#Sec15}
==========

Dialysis has a great impact on the HRQoL of ESRD patients and dialysis is a very expensive treatment. More than 80% of Dutch dialysis patients are treated with ICHD although home dialysis could result in a better HRQoL and could be more cost effective. Therefore, we initiated the DOMESTICO study, which will investigate the effects of home dialysis on HRQoL in relation to clinical outcomes and costs, in comparison with ICHD. This nationwide cohort study will include 1600 incident dialysis patients over a period of 3 years. At time of submission of this manuscript, 338 patients have been included.

Although a randomised controlled trial (RCT) would yield the ultimate answer to our research question, this is not in accordance with the concept of shared decision making. A patient's choice between home dialysis and ICHD is considered too fundamental, to let it be determined by chance. Indeed, an RCT in the Netherlands comparing PD with ICHD conducted in the past, stopped early due to poor patient recruitment; only 38 patients consented to be randomly assigned to either PD or ICHD \[[@CR64]\]. Hence, DOMESTICO is designed as a prospective, observational cohort study collecting extensive parameters to correct for confounding by indication.

The results of this study will be of great importance for future ESRD patients when choosing a treatment, as HRQoL is increasingly acknowledged by clinicians and patients as an important aspect in the decision-making process. In addition, the results with respect to clinical outcomes will ameliorate the shared decision-making process. Finally, the data could give more guidance to healthcare professionals, in particular to assess which type of patients may benefit most from home dialysis.

Additional file
===============

 {#Sec16}

Additional file 1:Local ethics committees/IRBs DOMESTICO. This file contains a list of the 44 (out of 53) local ethics committees from which approval for DOMESTICO is obtained. (DOCX 17 kb)

CCMO

:   Central Committee on Research Involving Human Subjects

CRF

:   Case report forms

DOMESTICO

:   Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes

DSI

:   Dialysis Symptom Index

EQ5D-5L

:   EuroQol-5D-5L

ESRD

:   End Stage Renal Disease

HHD

:   Home haemodialysis

HRQoL

:   Health-related quality of life

ICHD

:   In-centre haemodialysis

iMCQ

:   iMTA Medical Cost Questionnaire

iMTA

:   Institute for Medical Technology Assessment

iPCQ

:   iMTA Productivity Cost Questionnaire

MCS

:   Mental Component Summary

PCS

:   Physical Component Summary

PD

:   Peritoneal dialysis

PRO

:   Patient Reported Outcome

PROM

:   Patient Reported Outcome Measure

QALY

:   Quality adjusted life year

RCT

:   Randomised controlled trial

RRT

:   Renal replacement therapy

SeMaS

:   Self-management screening questionnaire

SF

:   Short Form
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